U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. OTC Monograph Reform: Overview of Draft Guidance for Formal Meetings - 03/29/2022
  1. News & Events for Human Drugs

Webcast | Virtual

Event Title
OTC Monograph Reform: Overview of Draft Guidance for Formal Meetings
March 29, 2022

Date:
March 29, 2022
Time:
2:00 PM - 3:00 PM ET

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS WEBINAR

During this webinar, FDA will provide an overview of the recently published draft guidance for industry titled Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs. FDA will also:

  • Provide an overview of OTC Monograph Reform
  • Explain OMUFA Timelines

TOPICS COVERED

  • Overview of OTC Monograph Reform
  • Overview of the formal monograph meetings draft guidance
  • Meeting types and formats
  • Content and format of meeting requests
  • Meeting request responses, meeting scheduling, and timelines
  • Meeting packages, preliminary responses, and meeting minutes
  • Rescheduling and canceling
  • Procedure for joint meetings
  • OMUFA timelines

INTENDED AUDIENCE

  • General public with an interest in nonprescription (also known as over-the-counter or OTC) drugs
  • Regulatory affairs professionals involved in the development or marketing of OTC drugs
  • Foreign regulators following the development or marketing of OTC drugs
  • Consultants focused on OTC drug development or marketing
  • Clinical research coordinators
  • Importers of OTC drugs

FDA SPEAKERS

Trang Tran
Commander, U.S. Public Health Service
Senior Regulatory Health Project Manager
Division of Nonprescription Drugs 1
Office of New Drugs(OND)
Office of Regulatory Operations (ORO)
Center for Drug Evaluation and Research (CDER) | US FDA

Elizabeth Thompson
Commander, U.S. Public Health Service
Chief, Project Management Staff
Division of Nonprescription Drugs 2
OND | ORO
CDER | US FDA

FDA RESOURCES

CONTINUING EDUCATION

Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations. Certificates are only available during the two weeks post-event.

This course has been:

  • pre-approved by RAPS as eligible for a maximum of 12 credits for a two day event (appropriate to real-time attendance) towards a participant’s RAC recertification upon full completion.
  • pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.
  • pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant’s RQAP re-registration.
  • approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.

TECHNICAL INFORMATION

  • To optimize your webinar experience, use Chrome when viewing Adobe Connect in a browser.
  • Please contact info@sbiaevents.com for all technical questions.
  • If you encounter any technical issues before or during the event, please visit the Technical Issues Support.
  • Test your PC for use with Adobe Connect prior to the day of the event. Adobe, the Adobe logo, Acrobat and Acrobat Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.
 
Back to Top